Rockefeller Capital Management
SAGE

Rockefeller Capital Management’s Sage Therapeutics SAGE Stock Holding History

Rockefeller Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed – – 4314
2022
Q2 		$0 Sell
20
-18
-47% -$603 ﹤0.01% 4358
2022
Q1 		$1K Buy
38
+19
+100% +$714 ﹤0.01% 3770
2021
Q4 		$0 Hold
19
– – ﹤0.01% 3966
2021
Q3 		$0 Sell
19
-550
-97% -$25.2K ﹤0.01% 3824
2021
Q2 		$32K Buy
569
+169
+42% +$11.9K ﹤0.01% 2272
2021
Q1 		$29K Buy
+400
New +$32.8K ﹤0.01% 2121
2020
Q1 		– Sell
-2,523
Closed -$182K – 2468
2019
Q4 		$182K Buy
+2,523
New +$310K ﹤0.01% 795
2019
Q2 		– Sell
-119
Closed -$19K – 1921
2019
Q1 		$19K Buy
+119
New +$17.2K ﹤0.01% 1266

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rockefeller Capital Management's SAGE Position: Q3 2022 in Review

Rockefeller Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 20 shares.

Rockefeller Capital Management first reported a position in SAGE in Q1 2019 and held it in 8 quarters. The position peaked at $182K in Q4 2019. 200 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • Rockefeller Capital Management reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 20 Sage Therapeutics shares in Q3 2022.
  • Rockefeller Capital Management first reported a position in Sage Therapeutics in Q1 2019 and held it in 8 quarters.
  • Rockefeller Capital Management's Sage Therapeutics position peaked at $182K in Q4 2019.
  • 200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Rockefeller Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.